Spectralis Optical Coherence Tomography for Evaluating Ocular Hypertensive and Glaucoma Suspect Eyes: Real-World Data from Taiwan

Spectralis光学相干断层扫描在评估眼高压和青光眼疑似病例中的应用:来自台湾的真实世界数据

阅读:1

Abstract

Objectives: The aim of this research was to evaluate the diagnostic performance of Spectralis optical coherence tomography (OCT) parameters for ocular hypertensive (OH) and glaucoma suspect (GS) eyes in an Asian population from Taiwan. Methods: This retrospective cross-sectional study included 258 OH (mean deviation [MD]: -1.10 ± 1.75 dB), 380 GS (MD: -1.24 ± 2.63 dB), and 742 normal (MD: -1.47 ± 3.29 dB) eyes. The diagnostic performance of Spectralis OCT parameters, including optic nerve head (ONH) and macular parameters, was compared among groups. The area under the receiver operating characteristic curve (AUC) of each parameter signified its power to differentiate between normal and OH or GS eyes. Results: In various scanning protocols, circumpapillary retinal nerve fiber layer (NFL)-temporal (AUC = 0.538), macular NFL-outer temporal (AUC = 0.611), and retinal average thickness (RAT)_1.8 (AUC = 0.578) were the best parameters in distinguishing OH eyes from normal eyes. Moreover, minimum rim width (MRW)-mean global (AUC = 0.737), macular NFL-outer temporal (AUC = 0.558), and RAT_2.8 (AUC = 0.543) were the best parameters in distinguishing GS eyes from normal eyes. After adjusting for age and refraction effects, we determined that the AUCs for OH and GS were 0.694 and 0.646, respectively. Conclusions: Our real-world data indicate that Spectralis OCT parameters show some potential for early glaucoma detection and monitoring, but their current diagnostic effectiveness remains limited. When managing OH eyes, caution is required in evaluating macular retinal NFL thickness in addition to the ONH. Bruch's membrane opening-MRW is a potential objective indicator of ONH changes in GS eyes.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。